ADC-2122 is under clinical development by Hangzhou Adcoris Biopharmaceutical and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADC-2122’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADC-2122 is under development for the treatment of advanced or metastatic solid tumors including breast cancer, colorectal cancer, lung cancer and gastric cancer. It is recombinant anti-human epidermal growth factor receptor humanized monoclonal antibody drug conjugate for injection coupled with dolastatin derivative DUO5 and the antibody part is a biosimilar of pertuzumab. It is administered through intravenous route and acts by targeting HER2.
Hangzhou Adcoris Biopharmaceutical overview
Hangzhou Adcoris Biopharmaceutical (Adcoris) is a clinical-stage biotechnology company. The company develops a new generation of antibody-targeted therapeutic drugs. Its product pipeline ADC2122 is a conjugate of an antibody against the HER2 target and DUO5. Adcoris also develops ADC2154, ADC2204, ADC2202, ADC2231, ADC2284, ADC2192, ADC2317, ADC2335, and ADC2312 for various solid tumoues. The company’s drug research and development platforms include the Adcoris-ADC platform and Adcoris-AXC which accelerates the design and synthesis of payload and linker. It develops drugs in the fields of tumor immunity, autoimmunity, infection, and metabolic diseases. The company works in collaboration with MabPlex, Tcelltech, GoBroad Healthcare Group, Shanghai Oriental Hospital, Teruisi, and ZBD Pharmaceutical for business development. Adcoris is headquartered in Hangzhou City, Zhejiang, China.
For a complete picture of ADC-2122’s drug-specific PTSR and LoA scores, buy the report here.